

# This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

**BUSY WEEK?** Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director *Patricia Van Arnum*.

**1. [Baxalta, Symphogen Ink \\$1.6 Billion Immuno-Oncology Deal](#)**

In yet another immuno-oncology deal, Baxalta Incorporated, the biopharmaceutical company spun off from Baxter in 2015, and Symphogen, a private Copenhagen, Denmark-based biopharmaceutical company developing recombinant antibodies and antibody mixtures, have formed a broad strategic immuno-oncology collaboration worth up to \$1.6 billion. [Read More](#)

**2. [Bayer Closes on \\$1 Billion Divestment of Diabetes Care Business](#)**

Bayer has closed on its previously announced agreement to sell its diabetes care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by the investment firm KKR and the Panasonic Corporation for EUR 1 billion (\$1.07 billion). The move is part of a portfolio adjustment as Bayer seeks to become a pure-play life sciences company. [Read More](#)

**3. [GSK Divests Rights for Ofatumumab to Novartis for up to \\$1 Billion](#)**

GlaxoSmithKline has completed its transaction to divest its rights to ofatumumab for auto-immune indications to Novartis Pharma AG, in deal valued up to \$1 billion. [Read More](#)

**4. [Takeda Buys Biologics Manufacturing Facility from Baxalta](#)**

Takeda Pharmaceutical Company Limited has acquired the biologics manufacturing facility located in Brooklyn Park, Minnesota, from Baxalta US Inc. Takeda intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products. [Read More](#)

**5. [Boehringer Ingelheim Plans Biopharmaceutical Manufacturing Expansion](#)**

Boehringer Ingelheim plans to invest approximately EUR 500 million (\$537 million) in biopharmaceutical production at its site in Vienna, Austria, through the addition of a new large-scale biopharmaceutical production facility for active ingredients manufactured using cell cultures. [Read More](#)

**6. [Mylan, Momenta Sign Biosimilars Pact](#)**

Mylan and Momenta Pharmaceuticals, Inc. have formed a collaboration to develop, manufacture, and commercialize six of Momenta's current biosimilar candidates, including Momenta's biosimilar candidate for Orencia (abatacept), Bristol-Myers Squibb's biologic for treating rheumatoid arthritis. [Read More](#)

**7. [Fresenius Kabi Acquires BD Manufacturing Plant](#)**

Fresenius Kabi has acquired from Becton, Dickinson and Company (BD) the BD Rx business, which includes a pharmaceutical manufacturing plant in Wilson, North Carolina, and the BD line of seven drugs in ready-to-administer prefilled glass syringes. The companies also signed a 10-year supply and distribution pact. [Read More](#)

## 8. [FDA Issues Draft Guidance on CMC Info for Emerging Manufacturing Technologies](#)

The FDA has issued draft guidance to provide recommendations to pharmaceutical companies interested in participating in a program involving the submission of chemistry, manufacturing, and controls (CMC) information containing emerging manufacturing technology to the FDA. [Read More](#)

## 9. [Teva, Takeda Offer Further Details of Generics JV in Japan](#)

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited have released further details on their generics joint venture in Japan, which the companies announced in late November 2015. [Read More](#)

## 10. [EMA, Regulatory Authorities Adopt Network Strategy](#)

The European Medicines Agency (EMA) Management Board and the Heads of Medicines Agencies (HMA) have adopted a common strategy to 2020 for the European medicines regulatory network, the first time that a single strategy for the whole network has been developed. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

---

### About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

[Forward this email](#)



This email was sent to [esanders@dcat.org](mailto:esanders@dcat.org) by [dcatnews@dcat.org](mailto:dcatnews@dcat.org) | [Update Profile/Email Address](#) | Rapid removal with [SafeUnsubscribe™](#) | [About our service provider.](#)

Drug, Chemical, & Associated Technologies Association | One Union Street | Suite 208 | Robbinsville | NJ | 08691